• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Novavax Inc.

    8/8/24 4:15:42 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    S-8 1 tm2421099d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on August 8, 2024

    Registration No. 333-       

     

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 

     

     

     

    NOVAVAX, INC.

    (Exact name of Registrant as specified in its charter)

      

    Delaware

    700 Quince Orchard Road

    Gaithersburg, Maryland 20878

    22-2816046
    (State of incorporation) (Address of principal executive offices) (I.R.S. Employer Identification No.)

     

      

    Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan

    Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan

    (Full Title of the Plan)

     

    MARK J. CASEY

    Executive Vice President, Chief Legal Officer & Corporate Secretary

    Novavax, Inc.

    700 Quince Orchard Road

    Gaithersburg, Maryland 20878

    (240) 268-2000

    (Name, Address and Telephone Number, Including Area Code, of Agent For Service)

     

    with copies to:

    PAUL M. KINSELLA

    TARA FISHER

    Ropes & Gray LLP

    800 Boylston Street

    Boston, Massachusetts 02199-3600

    (617) 951-7000

     

      

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

      

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) registers 1,810,264 additional shares of common stock, par value $0.01 per share (the “Common Stock”), of Novavax, Inc. (the “Registrant”) that may be issued and sold pursuant to the Registrant’s Amended and Restated 2013 Employee Stock Purchase Plan, as amended (the “2013 Plan”) and 6,500,000 additional shares of Common Stock that may be issued pursuant to awards under the Registrant’s Amended and Restated 2015 Stock Incentive Plan, as amended (the “2015 Plan”). This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities of the same class, and, pursuant to such instruction, the contents of the Registration Statement on Form S-8 (File No. 333-190599) filed with the Securities and Exchange Commission on August 13, 2013, the contents of the Registration Statement on Form S-8 (File No. 333-206354) filed with the Securities and Exchange Commission on August 13, 2015, the contents of the Registration Statement on Form S-8 (File No. 333-213069) filed with the Securities and Exchange Commission on August 11, 2016, the contents of the Registration Statement on Form S-8 (File No. 333-219829) filed with the Securities and Exchange Commission on August 9, 2017, the contents of the Registration Statement on Form S-8 (File No. 333-226498) filed with the Securities and Exchange Commission on August 1, 2018, the contents of the Registration Statement on Form S-8 (File No. 333-233133) filed with the Securities and Exchange Commission on August 8, 2019, the contents of the Registration Statement on Form S-8 (File No. 333-243758) filed with the Securities and Exchange Commission on August 10, 2020, the contents of the Registration Statement on Form S-8 (File No. 333-258517) filed with the Securities and Exchange Commission on August 5, 2021, the contents of the Registration Statement on Form S-8 (File No. 333-266681) filed with the Securities and Exchange Commission on August 9, 2022, and the contents of the Registration Statement on Form S-8 (File No. 333-273791) filed with the Securities and Exchange Commission on August 8, 2023, are each incorporated herein by reference.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    As permitted by Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants of the Registrant’s 2013 Plan and 2015 Plan, as applicable, as required by Rule 428(b) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Securities and Exchange Commission are hereby incorporated by reference in this Registration Statement on Form S-8:

     

      1. The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 28, 2024;
         
      2. The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarter ended March 31, 2024, filed on May 10, 2024, and for the fiscal quarter ended June 30, 2024, filed on August 8, 2024;
         
      3. The Registrant’s Current Reports on Form 8-K filed on January 31, 2024, February 22, 2024, March 26, 2024, April 26, 2024, May 13, 2024, May 23, 2024, June 6, 2024 (Item 8.01 only) and June 14, 2024 (except for portions of such reports which were furnished and not filed);
         
      4. The Registrant’s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2024, as amended by Amendment No. 1 to the Registrant's Definitive Proxy Statement on Schedule 14A, filed on June 5, 2024; and
         
      5. The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement No. 0-26770 on Form 10 filed on September 14, 1995 pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by any amendment or report filed for the purpose of updating such description, including the description of the Registrant’s Common Stock contained in Exhibit 4.4 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 28, 2024.

     

     

     

      

    All documents filed after the date of this Registration Statement by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all shares of Novavax, Inc.’s common stock offered hereunder have been sold or which deregisters all shares of Novavax, Inc. common stock remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is incorporated or deemed to be incorporated by reference herein, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 102 of the General Corporation Law of the State of Delaware (the “DGCL”) permits a corporation to eliminate the personal liability of its directors or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s second amended and restated certificate of incorporation (as amended) provides that no director shall be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is party or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.

     

     

     

     

    The Registrant’s second amended and restated certificate of incorporation (as amended) provides that it will indemnify each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Registrant) by reason of the fact that he or she is or was, or has agreed to become, its director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the Registrant, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful.

     

    The Registrant’s second amended and restated certificate of incorporation (as amended) also provides that it will indemnify any Indemnitee who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Registrant to procure a judgment in the Registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, its director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer or trustee or, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Registrant, unless and only to the extent that the Court of Chancery of Delaware determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the Registrant against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If the Registrant does not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.

     

    The Registrant has entered into indemnification agreements with its directors and certain of its officers, in addition to the indemnification provided for in its second amended and restated certificate of incorporation (as amended), and intends to enter into indemnification agreements with any new directors and executive officers in the future. The Registrant has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

     

     

     

    INDEX OF EXHIBITS

     

    Exhibit    
    Number   Description
    4.1   Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015)
    4.2   Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 9, 2019)
    4.3   Certificate of Designation of Series A Convertible Preferred Stock of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 19, 2020)
    4.4   Amended and Restated By-Laws of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on April 26, 2024)
    5.1*   Opinion of Ropes & Gray LLP
    10.1   Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan (Incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement filed on April 29, 2024, in connection with the Annual Meeting held on June 13, 2024)
    10.2   Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (Incorporated by reference to Appendix B of the Registrant’s Definitive Proxy Statement filed on April 29, 2024, in connection with the Annual Meeting held on June 13, 2024)
    23.1*   Consent of Ropes & Gray LLP (included in Exhibit 5.1)
    23.2*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
    24.1*   Power of Attorney to file future amendments (included on the signature page of this Registration Statement)
    107.1*   Filing Fee Table

     

    * Filed herewith

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; Provided however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

     

     

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Gaithersburg, state of Maryland on August 8, 2024.

     

      NOVAVAX, INC.
       
      By: /s/ John C. Jacobs
        John C. Jacobs
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints John C. Jacobs, James P. Kelly and Mark J. Casey, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Novavax, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

      

    Signature    Title    Date 
             
    /s/ John C. Jacobs   President and Chief Executive Officer   August 8, 2024
    John C. Jacobs   and Director (Principal Executive Officer)    
             
    /s/ James P. Kelly   Executive Vice President, Chief Financial Officer   August 8, 2024
    James P. Kelly   and Treasurer (Principal Financial and Accounting Officer)    
             
    /s/ James F. Young   Chairman of the Board of Directors   August 8, 2024
    James F. Young        
             
    /s/ Gregg H. Alton   Director   August 8, 2024
    Gregg H. Alton        
             
    /s/ Richard H. Douglas   Director   August 8, 2024
    Richard H. Douglas        
             
    /s/ Rachel K. King   Director   August 8, 2024
    Rachel K. King        
             
    /s/ Margaret G. McGlynn   Director   August 8, 2024
    Margaret G. McGlynn        
             
    /s/ David M. Mott   Director   August 8, 2024
    David M. Mott        
             
    /s/ Richard J. Rodgers   Director   August 8, 2024
    Richard J. Rodgers        

     

     

     

    Get the next $NVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    10/24/2025$18.00Overweight
    Cantor Fitzgerald
    8/28/2025$10.00Buy
    H.C. Wainwright
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    6/17/2025$6.00Sell
    Citigroup
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    More analyst ratings

    $NVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on Novavax with a new price target

    Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00

    10/24/25 8:05:21 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Novavax with a new price target

    H.C. Wainwright resumed coverage of Novavax with a rating of Buy and set a new price target of $10.00

    8/28/25 8:09:49 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax downgraded by BofA Securities with a new price target

    BofA Securities downgraded Novavax from Neutral to Underperform and set a new price target of $7.00

    8/20/25 8:27:13 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Novavax Inc.

    SCHEDULE 13G - NOVAVAX INC (0001000694) (Subject)

    2/9/26 7:56:48 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - NOVAVAX INC (0001000694) (Filer)

    1/20/26 6:59:39 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NOVAVAX INC (0001000694) (Filer)

    1/12/26 8:01:06 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Novavax Announces Entering into a License Agreement with Pfizer

    Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its productsProvides Novavax with an upfront payment of $30 million with the potential for up to another $500 million in development and sales milestones. In addition to milestone payments, Novavax is eligible to receive high mid-single digit percentage royaltiesGAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of the agreement, Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizer's products in up to two disease areas. "The Novavax

    1/20/26 7:15:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the 44th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation Date:                     Wednesday, January 14, 2026 Time:                     4:30 p.m. Pacific Time Location:                     San Francisco, CA A webcast of the presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven techn

    1/7/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Participate in Jefferies London Healthcare Conference

    GAITHERSBURG, Md., Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat Date: Wednesday, November 19, 2025 Time: 4:30 p.m. Greenwich Mean Time Location: London, United Kingdom A webcast of the fireside chat will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days. About NovavaxNovavax, Inc. (NASDAQ:NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including prote

    11/12/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Jacobs John C covered exercise/tax liability with 39,132 shares and converted options into 83,197 shares, increasing direct ownership by 32% to 180,797 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    1/26/26 7:57:59 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, Chief Legal Officer Casey Mark J converted options into 41,899 shares and covered exercise/tax liability with 12,713 shares, increasing direct ownership by 91% to 61,159 units (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    12/15/25 4:01:11 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Section 16 Draghia-Akli Ruxandra converted options into 14,257 shares and covered exercise/tax liability with 6,048 shares (SEC Form 4)

    4 - NOVAVAX INC (0001000694) (Issuer)

    11/13/25 5:23:25 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Charles Newton to Board of Directors

    GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

    4/29/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

    Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

    1/23/25 9:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

    Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

    9/25/24 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Financials

    Live finance-specific insights

    View All

    Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

    Total revenue of $70 million in the third quarter of 2025Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfersSanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid™ in combination with both Fluzone High-Dose and FlublokSanofi received BARDA grant for pandemic influenza vaccine candidate using Novavax's Matrix-M® adjuvantMaryland site consolidation transactions resulted in $60 million cash proceeds and approximately $230 million in expected future cost savingsRaises Full Year 2025 Revenue Framework and Affirms Financial GuidanceCompany to

    11/6/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025

    GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows: Conference call details:  Date:                                November 6, 2025 Time:                              8:30 a.m. ET URL to register phone:    Register Here Dial-in number:              (888) 880-3330 (U.S.) or (+1) (646) 357-8766 (International) Webcast:                        ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering thei

    10/30/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

    Total revenue of $239 million in the second quarter of 2025Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval triggered $175 million milestone payment from SanofiCompleted transition of Nuvaxovid™ commercial leadership in the U.S. to Sanofi for the 2025-2026 COVID-19 vaccination season  COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses in initial cohort of a Phase 3 trial with new T-cell response data in both Novavax vaccine candidates numerically higher than in the comparator Fluzone HD armUpdated Full Year 2025 Revenue Framework and Financial Guidanc

    8/6/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/12/24 4:46:17 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/4/24 1:19:04 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    7/10/24 6:16:55 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care